Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Young adults diagnosed with high grade gliomas: Patterns of care, outcomes, and impact on employment.

Hafeez U, Menon S, Nguyen B, Lum C, Gaughran G, Pranavan G, Cher L, Nowak AK, Gan HK, Parakh S.

J Clin Neurosci. 2019 Jul 29. pii: S0967-5868(19)30435-7. doi: 10.1016/j.jocn.2019.07.063. [Epub ahead of print]

PMID:
31371189
2.

First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.

Gan HK, Millward M, Hua Y, Qi C, Sai Y, Su W, Wang J, Zhang L, Frigault MM, Morgan S, Yang L, Lickliter JD.

Clin Cancer Res. 2019 Aug 15;25(16):4924-4932. doi: 10.1158/1078-0432.CCR-18-1189. Epub 2019 Apr 5.

PMID:
30952639
3.

BI 853520, a FAK-Simile of Prior FAK Inhibitors?

Lee RC, Gan HK.

Target Oncol. 2019 Feb;14(1):39-41. doi: 10.1007/s11523-019-00621-z. No abstract available.

PMID:
30843167
4.

Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.

Lassman AB, Roberts-Rapp L, Sokolova I, Song M, Pestova E, Kular R, Mullen C, Zha Z, Lu X, Gomez E, Bhathena A, Maag D, Kumthekar P, Gan HK, Scott AM, Guseva M, Holen KD, Ansell PJ, van den Bent MJ.

Clin Cancer Res. 2019 Jun 1;25(11):3259-3265. doi: 10.1158/1078-0432.CCR-18-3034. Epub 2019 Feb 22.

PMID:
30796037
5.

Changes in the Use of Comprehensive Geriatric Assessment in Clinical Trials for Older Patients with Cancer over Time.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J.

Oncologist. 2019 Aug;24(8):1089-1094. doi: 10.1634/theoncologist.2018-0493. Epub 2019 Feb 1.

PMID:
30710065
6.

A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.

Arnaud-Coffin P, Maillet D, Gan HK, Stelmes JJ, You B, Dalle S, Péron J.

Int J Cancer. 2019 Aug 1;145(3):639-648. doi: 10.1002/ijc.32132. Epub 2019 Feb 4.

PMID:
30653255
7.

A single-institution prospective evaluation of a neuro-oncology multidisciplinary team meeting.

Ameratunga M, Miller D, Ng W, Wada M, Gonzalvo A, Cher L, Gan HK.

J Clin Neurosci. 2018 Oct;56:127-130. doi: 10.1016/j.jocn.2018.06.032. Epub 2018 Jun 29.

PMID:
30318071
8.

Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a.

Burvenich IJG, Parakh S, Lee FT, Guo N, Liu Z, Gan HK, Rigopoulos A, O'Keefe GJ, Gong SJ, Goh YW, Tochon-Danguy H, Scott FE, Kotsuma M, Hirotani K, Senaldi G, Scott AM.

Theranostics. 2018 Jul 30;8(15):4199-4209. doi: 10.7150/thno.25575. eCollection 2018.

9.

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.

Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R.

Neuro Oncol. 2019 Jan 1;21(1):106-114. doi: 10.1093/neuonc/noy091.

10.

Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients.

Arulananda S, Lynam J, Sem Liew M, Wada M, Cher L, Gan HK.

Intern Med J. 2018 Oct;48(10):1206-1214. doi: 10.1111/imj.14000.

PMID:
29923272
11.

Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases.

Hafeez U, Gan HK, Scott AM.

Curr Opin Pharmacol. 2018 Aug;41:114-121. doi: 10.1016/j.coph.2018.05.010. Epub 2018 Jun 5. Review.

PMID:
29883853
12.

Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies.

Brastianos PK, Ippen FM, Hafeez U, Gan HK.

Oncologist. 2018 Sep;23(9):1063-1075. doi: 10.1634/theoncologist.2017-0614. Epub 2018 Apr 27. Review.

PMID:
29703764
13.

Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort.

Bernstein LJ, Pond GR, Gan HK, Tirona K, Chan KK, Hope A, Kim J, Chen EX, Siu LL, Razak ARA.

Head Neck. 2018 Sep;40(9):2029-2042. doi: 10.1002/hed.25198. Epub 2018 Apr 17.

PMID:
29667262
14.

Receptor Occupancy Imaging Studies in Oncology Drug Development.

Burvenich IJG, Parakh S, Parslow AC, Lee ST, Gan HK, Scott AM.

AAPS J. 2018 Mar 8;20(2):43. doi: 10.1208/s12248-018-0203-z. Review.

PMID:
29520671
15.

Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.

Phillips AC, Boghaert ER, Vaidya KS, Falls HD, Mitten MJ, DeVries PJ, Benatuil L, Hsieh CM, Meulbroek JA, Panchal SC, Buchanan FG, Durbin KR, Voorbach MJ, Reuter DR, Mudd SR, Loberg LI, Ralston SL, Cao D, Gan HK, Scott AM, Reilly EB.

Mol Cancer Ther. 2018 Apr;17(4):795-805. doi: 10.1158/1535-7163.MCT-17-0710. Epub 2018 Feb 26.

16.

Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer.

Zer A, Pond GR, Razak ARA, Tirona K, Gan HK, Chen EX, O'Sullivan B, Waldron J, Goldstein DP, Weinreb I, Hope AJ, Kim JJ, Chan KKW, Chan AK, Siu LL, Bernstein LJ.

JAMA Otolaryngol Head Neck Surg. 2018 Jan 1;144(1):71-79. doi: 10.1001/jamaoto.2017.2235.

17.

Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.

Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, Gomez EJ, Fischer J, Mandich H, Xiong H, Lee HJ, Munasinghe WP, Roberts-Rapp LA, Ansell PJ, Holen KD, Kumthekar P.

Neuro Oncol. 2018 May 18;20(6):838-847. doi: 10.1093/neuonc/nox202.

18.

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26.

19.

Changes in the use of end points in clinical trials for elderly cancer patients over time.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J.

Ann Oncol. 2017 Oct 1;28(10):2606-2611. doi: 10.1093/annonc/mdx354.

PMID:
28961850
20.

Evolution of anti-HER2 therapies for cancer treatment.

Parakh S, Gan HK, Parslow AC, Burvenich IJG, Burgess AW, Scott AM.

Cancer Treat Rev. 2017 Sep;59:1-21. doi: 10.1016/j.ctrv.2017.06.005. Epub 2017 Jul 6. Review.

PMID:
28715775
21.

Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.

Gan HK, van den Bent M, Lassman AB, Reardon DA, Scott AM.

Nat Rev Clin Oncol. 2017 Nov;14(11):695-707. doi: 10.1038/nrclinonc.2017.95. Epub 2017 Jul 4. Review.

PMID:
28675164
22.

Antibody-Drug Conjugates for Cancer Therapy.

Parslow AC, Parakh S, Lee FT, Gan HK, Scott AM.

Biomedicines. 2016 Jul 11;4(3). pii: E14. doi: 10.3390/biomedicines4030014. Review.

23.

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.

Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, Fichtel L, Sulman EP, Gomez E, Fischer J, Lee HJ, Munasinghe W, Xiong H, Mandich H, Roberts-Rapp L, Ansell P, Holen KD, Gan HK.

Neuro Oncol. 2017 Jul 1;19(7):965-975. doi: 10.1093/neuonc/now257.

24.

In Vitro and In Vivo Evaluation of 89Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy.

Burvenich IJ, Lee FT, Guo N, Gan HK, Rigopoulos A, Parslow AC, O'Keefe GJ, Gong SJ, Tochon-Danguy H, Rudd SE, Donnelly PS, Kotsuma M, Ohtsuka T, Senaldi G, Scott AM.

Theranostics. 2016 Sep 25;6(12):2225-2234. eCollection 2016.

25.

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.

Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, Evans TR, Zalcman G, Bahleda R, Hollebecque A, Lemech C, Dean E, Brown J, Gibson D, Peddareddigari V, Murray S, Nebot N, Mazumdar J, Swartz L, Auger KR, Fleming RA, Singh R, Millward M.

Ann Oncol. 2016 Dec;27(12):2268-2274. doi: 10.1093/annonc/mdw427. Epub 2016 Oct 11.

PMID:
27733373
26.

L-Tyrosine Confers Residualizing Properties to a d-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies.

Lee FT, Burvenich IJ, Guo N, Kocovski P, Tochon-Danguy H, Ackermann U, O'Keefe GJ, Gong S, Rigopoulos A, Liu Z, Gan HK, Scott AM.

Mol Imaging. 2016 Jul 25;15. pii: 1536012116647535. doi: 10.1177/1536012116647535. Print 2016.

27.

Inclusion of elderly patients in oncology clinical trials.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J.

Ann Oncol. 2016 Sep;27(9):1799-804. doi: 10.1093/annonc/mdw259. Epub 2016 Jun 29.

PMID:
27358382
28.

Temozolomide-Associated Liver Fibrosis.

Parakh S, Hamid A, Cher L, Gan HK.

J Clin Pharmacol. 2016 Nov;56(11):1448-1449. doi: 10.1002/jcph.753. No abstract available.

PMID:
27094014
29.

Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a.

Burvenich IJ, Parakh S, Gan HK, Lee FT, Guo N, Rigopoulos A, Lee ST, Gong S, O'Keefe GJ, Tochon-Danguy H, Kotsuma M, Hasegawa J, Senaldi G, Scott AM.

J Nucl Med. 2016 Jun;57(6):974-80. doi: 10.2967/jnumed.115.169839. Epub 2016 Mar 3.

30.

Antibody-mediated delivery of therapeutics for cancer therapy.

Parakh S, Parslow AC, Gan HK, Scott AM.

Expert Opin Drug Deliv. 2016;13(3):401-19. doi: 10.1517/17425247.2016.1124854. Epub 2015 Dec 19. Review.

PMID:
26654403
31.

Gender, Race, and Age at Diagnosis as Risk Factors for Metastasis or Recurrence among 1,657 Thyroid Cancer Patients Treated with Radioiodine across 40 Years in Singapore.

Kao YH, Gan HK, Zaheer S, Lam WW, Loke KS, Wong WY, Ng DC, Goh AS.

Oncol Res Treat. 2015;38(12):679-82. doi: 10.1159/000442114. Epub 2015 Nov 18.

PMID:
26633801
32.

Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.

Maillet D, Gan HK, Blay JY, You B, Péron J.

Eur J Cancer. 2016 Jan;52:26-32. doi: 10.1016/j.ejca.2015.08.025. Epub 2015 Nov 27. Review.

PMID:
26630531
33.

Recurrent glioblastoma: Current patterns of care in an Australian population.

Parakh S, Thursfield V, Cher L, Dally M, Drummond K, Murphy M, Rosenthal MA, Gan HK.

J Clin Neurosci. 2016 Feb;24:78-82. doi: 10.1016/j.jocn.2015.08.025. Epub 2015 Nov 6.

PMID:
26549675
34.

The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members.

Maillet D, Blay JY, You B, Rachdi A, Gan HK, Péron J.

Ann Oncol. 2016 Jan;27(1):192-8. doi: 10.1093/annonc/mdv485. Epub 2015 Oct 19.

PMID:
26483049
35.

First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.

Whittle JR, Lickliter JD, Gan HK, Scott AM, Simes J, Solomon BJ, MacDiarmid JA, Brahmbhatt H, Rosenthal MA.

J Clin Neurosci. 2015 Dec;22(12):1889-94. doi: 10.1016/j.jocn.2015.06.005. Epub 2015 Aug 13.

PMID:
26279503
36.

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.

Ciprotti M, Tebbutt NC, Lee FT, Lee ST, Gan HK, McKee DC, O'Keefe GJ, Gong SJ, Chong G, Hopkins W, Chappell B, Scott FE, Brechbiel MW, Tse AN, Jansen M, Matsumura M, Kotsuma M, Watanabe R, Venhaus R, Beckman RA, Greenberg J, Scott AM.

J Clin Oncol. 2015 Aug 20;33(24):2609-16. doi: 10.1200/JCO.2014.60.4256. Epub 2015 Jun 29.

37.

Management of glioblastoma in Victoria, Australia (2006-2008).

Gan HK, Rosenthal MA, Cher L, Dally M, Drummond K, Murphy M, Thursfield V.

J Clin Neurosci. 2015 Sep;22(9):1462-6. doi: 10.1016/j.jocn.2015.03.029.

PMID:
26117358
38.

Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib.

Richter S, Seah JA, Pond GR, Gan HK, Mackenzie MJ, Hotte SJ, Mukherjee SD, Murray N, Kollmannsberger C, Heng D, Haider MA, Halford R, Ivy SP, Moore MJ, Sridhar SS.

Can Urol Assoc J. 2014 Nov;8(11-12):398-402. doi: 10.5489/cuaj.2426.

39.

Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy.

Bylicki O, Gan HK, Joly F, Maillet D, You B, Péron J.

Ann Oncol. 2015 Jan;26(1):231-7. doi: 10.1093/annonc/mdu489. Epub 2014 Oct 29.

PMID:
25355720
40.

Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma.

Ciprotti M, Chong G, Gan HK, Chan A, Murone C, MacGregor D, Lee FT, Johns TG, Heath JK, Ernst M, Burgess AW, Scott AM.

EJNMMI Res. 2014 May 30;4:22. doi: 10.1186/s13550-014-0022-x. eCollection 2014.

41.

Mistaken identity: granular cell astrocytoma masquerading as histiocytosis of the central nervous system.

Campbell RN, Liew MS, Gan HK, Cher L.

J Clin Neurosci. 2014 Aug;21(8):1457-9. doi: 10.1016/j.jocn.2013.10.037. Epub 2014 Feb 6.

PMID:
24594450
42.

Author reply: To PMID 23279053.

Wong SF, Mak G, Rosenthal MA, Cher L, Gan HK.

Intern Med J. 2014 Feb;44(2):210-1. doi: 10.1111/imj.12338. No abstract available.

PMID:
24528822
43.

Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review.

Péron J, Maillet D, Gan HK, Chen EX, You B.

J Clin Oncol. 2013 Nov 1;31(31):3957-63. doi: 10.1200/JCO.2013.49.3981. Epub 2013 Sep 23. Review.

PMID:
24062406
44.

Curcumin ameliorates dextran sulfate sodium-induced experimental colitis by blocking STAT3 signaling pathway.

Liu L, Liu YL, Liu GX, Chen X, Yang K, Yang YX, Xie Q, Gan HK, Huang XL, Gan HT.

Int Immunopharmacol. 2013 Oct;17(2):314-20. doi: 10.1016/j.intimp.2013.06.020. Epub 2013 Jul 12.

PMID:
23856612
45.

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.

Gan HK, Cvrljevic AN, Johns TG.

FEBS J. 2013 Nov;280(21):5350-70. doi: 10.1111/febs.12393. Epub 2013 Jul 8. Review.

46.

Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.

Chang JH, Wada M, Anderson NJ, Lim Joon D, Lee ST, Gong SJ, Gunawardana DH, Sachinidis J, O'Keefe G, Gan HK, Khoo V, Scott AM.

Acta Oncol. 2013 Nov;52(8):1723-9. doi: 10.3109/0284186X.2012.759273. Epub 2013 Jan 15.

PMID:
23317145
47.

Local perspective on a rare brain tumour: adult medulloblastoma.

Wong SF, Mak G, Rosenthal MA, Cher L, Gan HK.

Intern Med J. 2013 May;43(5):567-72. doi: 10.1111/imj.12060. Review.

PMID:
23279053
48.

Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents.

Le Tourneau C, Gan HK, Razak AR, Paoletti X.

PLoS One. 2012;7(12):e51039. doi: 10.1371/journal.pone.0051039. Epub 2012 Dec 12.

49.

Influence of statistician involvement on reporting of randomized clinical trials in medical oncology.

Péron J, You B, Gan HK, Maillet D, Chen EX, Pond GR.

Anticancer Drugs. 2013 Mar;24(3):306-9. doi: 10.1097/CAD.0b013e32835c3561.

PMID:
23221738
50.

A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide.

Wong SF, Gan HK, Cher L.

J Clin Neurosci. 2012 Nov;19(11):1501-5. doi: 10.1016/j.jocn.2012.04.001. Epub 2012 Sep 17.

PMID:
22995759

Supplemental Content

Support Center